-Results demonstrated that KL1333 was safe and well tolerated, with early signs of efficacy in patients with primary mitochondrial disease- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company ...

-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage compa ...

-With 24 weeks of dosing complete, Abliva remains on track to report the interim analysis in early Q3 2024- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for [&helli ...

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the goal of enrolling 40 patients ...

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has gr ...

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company has now included the t ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will participate in W ...

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company’s lead candidate KL133 ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will present at UMDF’ ...

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the first patient has been dosed ...